Associate Professor Chien-Yi Hsu
Taipei Medical University Hospital, Taipei (Taiwan)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Tumor necrosis factor superfamily 14 (TNFSF14/ LIGHT) attenuates neovascularization by reducing circulating endothelial progenitor cells and function
Event: ESC Congress 2023
Topic: Microcirculation, Angiogenesis, Arteriogenesis
Session: Macro- and microvasculature
Real world experience on angiotensin receptor and neprilysin inhibition in reduced ejection fraction heart failure patients with advanced chronic kidney disease
Event: ESC Congress 2020
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Session: Chronic Heart Failure ePosters
Effect of de-escalated switching dual antiplatelet therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: real-world data from a nationwide cohort study
Event: ESC Congress 2019
Topic: Antiplatelet Drugs
Session: Evolving developments in anti-platelet therapy
Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy
Event: Heart Failure 2019
Topic: Pharmacotherapy
Session: Chronic Heart Failure – Treatment
Real world experience on angiotensin receptor and neprilysin inhibition in reduced ejection fraction heart failure patients with advanced chronic kidney disease
Event: ESC Asia with APSC & AFC 2020
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Session: Abstract Programme
ESC 365 is supported by
